108 Biocapital Growth Fund, LP

108 Biocapital Growth Fund, LP

108 Biocapital Growth Fund, LP launched in 2020 as a dedicated life sciences venture fund focused on growth-stage investments. The fund's mandate covers biotechnology, specialty pharmaceuticals, and medical devices within North America. The fund invests at Series C and later rounds, targeting companies with phase 2 or later clinical data and commercial-scale manufacturing capabilities. It has co-invested with larger biotech venture firms on several rounds, though the public record is limited. Investments span therapeutic areas including oncology, neurology, and rare diseases. The fund's total AUM is estimated at $10-50 million based on typical fund sizes for managers in this strategy and vintage. The team size and principal names are not publicly documented. No adjacent philanthropic structures have been identified. The fund maintains a focused investment thesis on late-stage science rather than discovery-stage platforms. Its deal sourcing relies on relationships with research institutions and licensing partners.